Bristol Myers collaborates with Microsoft to use AI technology for identifying lung cancer

Bristol Myers Squibb Partners with Microsoft to Advance Lung Cancer Detection Using AI

Bristol Myers Squibb announced on Tuesday a new partnership with Microsoft to leverage the tech giant’s artificial intelligence-powered radiology platform, aiming to accelerate the early identification of lung cancer.

This initiative will utilize FDA-approved radiology AI tools through Microsoft’s Precision Imaging Network. The platform examines X-ray and CT scans to detect signs of lung disease and is already in use at hospitals throughout the United States, according to both companies.

The pharmaceutical company highlighted that these AI solutions could assist healthcare professionals in detecting subtle lung nodules and diagnosing patients at earlier stages of lung disease.

A major focus of the collaboration is to broaden access to early detection, particularly in underserved areas such as rural hospitals and community clinics across the country.

Alexandra Goncalves, Vice President and Head of Digital Health at Bristol Myers Squibb, stated, “By merging Microsoft’s scalable radiology technology with our expertise in oncology and drug development, we are creating an innovative AI-driven workflow. This will enable clinicians to efficiently and accurately identify individuals with non-small cell lung cancer and connect them to the most effective treatment options and targeted therapies.”

The pharmaceutical industry is increasingly embracing artificial intelligence to boost research and development, with hopes that advanced modeling and automation will streamline their processes.

In related news, AstraZeneca recently revealed plans to acquire Modella AI, a Boston-based company, to enhance the pace of its cancer drug research.

Reported by Sneha S K in Bengaluru; Edited by Tasim Zahid